Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04921358
Recruitment Status : Recruiting
First Posted : June 10, 2021
Last Update Posted : September 23, 2021
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody, with the anti-PD-(L)1 antibody administered in combination with or following platinum-based chemotherapy.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer (NSCLC) Drug: Tislelizumab in combination with Sitravatinib Drug: Docetaxel Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody
Actual Study Start Date : July 27, 2021
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Arm A: Tislelizumab in combination with Sitravatinib
tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day
Drug: Tislelizumab in combination with Sitravatinib
Tislelizumab 200 mg intravenously once every 3 weeks in combination with sitravatinib 100 mg orally once a day, A cycle is 21 days in length ± 3 days, to be administered until Progressive Disease or intolerable toxicity

Active Comparator: Arm B: Docetaxel
docetaxel 75 mg/m2 intravenously once every 3 weeks
Drug: Docetaxel
Docetaxel 75 mg/m2 intravenously once every 3 weeks, A cycle is 21 days in length ± 3 days, to be administered until Progressive Disease or intolerable toxicity.




Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: From first randomization up to 35 months, approximately ]
    OS is defined as the time from first study drug administration to the date of death due to any reason.

  2. Progression-free survival (PFS) as assessed by Independent Review Committee (IRC) [ Time Frame: From first randomization up to 35 months, approximately ]
    defined as the time from randomization to the first occurrence of disease progression as determined by the IRC based on RECIST v1.1, or death from any cause, whichever occurs first


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: From first randomization up to 35 months, approximately ]
    defined as the time from randomization to the first occurrence of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occurs first

  2. Overall response rate (ORR) [ Time Frame: From first randomization up to 35 months, approximately ]
    defined as the proportion of participants with partial response or complete response as determined by the IRC based on RECIST v1.1

  3. Disease control rate (DCR) [ Time Frame: From first randomization up to 35 months, approximately ]
    defined as the proportion of participants whose best overall response (BOR) is complete response, partial response or stable disease as determined by the IRC based on RECIST v1.1

  4. Health-related quality of life (HRQoL) as assessed according to the European Organization and Treatment of Cancer lung cancer module, QLQ-LC13 [ Time Frame: From first randomization up to 35 months, approximately ]
    A score of 1-4 will be administrated for each item in QLQ-LC13. The higher scores will indicate the worse outcomes.

  5. Health-related quality of life (HRQoL) as assessed according to the European Organization for Research and Treatment of Cancer (EORTC) core cancer (QLQ-C30) [ Time Frame: From first randomization up to 35 months, approximately ]
    The EORTC QLQ-C30 is completed by the participant. The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

  6. Health-related quality of life (HRQoL) as assessed according to the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) [ Time Frame: From first randomization up to 35 months, approximately ]
    Patient-reported outcomes based on EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) for all cohorts The EQ-5D- is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system has two versions, namely the 3L and 5L, both involving five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the EQ-5D-5L that will be used, participants may choose from the following five response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

  7. Number of participants experiencing treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 [ Time Frame: From first randomization up to 35 months, approximately ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Metastatic or unresectable locally advanced histologically confirmed Non-Small Cell Lung Cancer (NCSLC), not amenable to treatment with curative intent
  2. Able to provide archival/fresh tumor tissues for biomarker analysis to assess PD-L1 expression and other biomarkers.
  3. No known Epidermal Growth Factor Receptor (EGFR) or BRAF mutation, or ALK rearrangement or ROS1 rearrangement
  4. Radiographic progression per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 on or after anti-PD-(L)1 containing therapy as the most recent treatment for locally advanced and unresectable or metastatic NSCLC.
  5. At least 1 measurable lesion as defined based on RECIST v1.1 by investigator

Key Exclusion Criteria:

  1. Has received docetaxel as monotherapy or in combination with other therapies.
  2. Squamous NSCLC with central cavitation, or NSCLC with hemoptysis (> 50 mL/day)
  3. Participants with tumor shown by imaging to be located around important vascular structures or if the investigator determines that the tumor is likely to invade important blood vessels and may cause fatal bleeding.
  4. Active leptomeningeal disease for metastatic NSCLC or uncontrolled, untreated brain metastasis.
  5. Active autoimmune diseases or history of autoimmune diseases that may relapse.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04921358


Contacts
Layout table for location contacts
Contact: BeiGene 1-877-828-5568 clinicaltrials@beigene.com

Locations
Show Show 58 study locations
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: Cheng Chen BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT04921358    
Other Study ID Numbers: BGB-A317-Sitravatinib 301
First Posted: June 10, 2021    Key Record Dates
Last Update Posted: September 23, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action